Method of making a sol-gel glass body and removing same from mold

The disclosed method of making a glass body by a sol/gel process comprises electrochemically assisted release of the gel body from the mold in which the body was formed. More specifically, the method involves gelation of a sol in a mold that comprises a first conductor member, with a second conductor member also being in contact with the sol and/or gel, and causing the flow of a current between the first and second conductor members, with the first member being the cathode. In consequence of the current flow a substantially liquid lubricating layer that facilitates removal of the gel body from the melt exists at the cathode/gel interface.Published versio

Microwave Gaseous Discharges

Contains reports on four research projects.United States Atomic Energy Commission (Contract AT(30-1)-1842

Atlas of Electrochemical Equilibria in Aqueous Solutions

ABSTRACT The electrodeposition of Sn/Pb alloys and the effect of surface agents was studied in fluoboric acid solutions. Smooth, semibright deposits have been produced at current densities in excess of 800 mA/cm 2, approaching the mass transfer limited current. Dendrite suppression (microleveling) has been achieved by the addition of polymeric sulfactant and uniform current distributions have been obtained by the addition of lactones or other related species. When the two adsorbed species are used simultaneously the solution concentration of metal ions and the additive ratio dictate the deposition parameters. The additives have been found to be chemically more stable, less costly, and allow current densities in excess of 20x those in current commercial use

Characterization and Performance of PADME's Cherenkov-Based Small-Angle Calorimeter

The PADME experiment, at the Laboratori Nazionali di Frascati (LNF), in Italy, will search for invisible decays of the hypothetical dark photon via the process $e^+e^-\rightarrow \gamma A'$, where the $A'$ escapes detection. The dark photon mass range sensitivity in a first phase will be 1 to 24 MeV. We report here on measurement and simulation studies of the performance of the Small-Angle Calorimeter, a component of PADME's detector dedicated to rejecting 2- and 3-gamma backgrounds. The crucial requirement is a timing resolution of less than 200 ps, which is satisfied by the choice of PbF$_2$ crystals and the newly released Hamamatsu R13478UV photomultiplier tubes (PMTs). We find a timing resolution of 81 ps (with double-peak separation resolution of 1.8 ns) and a single-crystal energy resolution of 5.7%/$\sqrt{E}$ with light yield of 2.07 photo-electrons per MeV, using 100 to 400 MeV electrons at the Beam Test Facility of LNF. We also propose the investigation of a two-PMT solution coupled to a single PbF$_2$ crystal for higher-energy applications, which has potentially attractive features.Comment: 12 pages, 19 figures. v2: added section on radiation damage studie

Critical Reflections on Thinking, Practice, Content and Consequences

nonPeerReviewe

Plasma Dynamics

Contains reports on three research projects.United States Atomic Energy Commission (Contract AT(30-1)-1842)United States Air Force, Air Force Cambridge Research Center, Air Research and Development Command (Contract AF19(604)-4551

Hydrolysis of nucleoside di- and triphosphates by crystalline preparations of yeast inorganic pyrophosphatase

1. 1. Crystalline preparations of yeast inorganic pyrophosphatase catalyze phosphate liberation from ATP and ADP, as well as from pyrophosphate, in the presence of zinc ions.2. 2. A variety of other nucleoside di- and triphosphates are hydrolyzed in the presence of zinc ions and pyrophosphatase, and manganous and cobaltous ions can partially substitute for zinc in effecting ATP hydrolysis.3. 3. Although several lines of evidence suggest that a single protein possesses Mg++-pyrophosphatase and Zn++-ATPase activities, the possibility cannot be eliminated that a different protein, present in small amounts, accounts for the ATPase activity.4. 4. Evidence has been obtained that the hydrolysis of ATP occurs primarily between the [beta]- and [gamma]-phosphate groups to yield ADP, which is then converted to AMP.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/32415/1/0000492.pd

Metabolism within the tumor microenvironment and its implication on cancer progression: an ongoing therapeutic target

Since reprogramming energy metabolism is considered a new hallmark of cancer, tumor metabolism is again in the spotlight of cancer research. Many studies have been carried out and many possible therapies have been developed in the last years. However, tumor cells are not alone. A series of extracellular components and stromal cells, such as endothelial cells, cancer-associated fibroblasts, tumor-associated macrophages and tumor-infiltrating T cells, surround tumor cells in the so-called tumor microenvironment. Metabolic features of these cells are being studied in deep in order to find relationships between metabolism within the tumor microenvironment and tumor progression. Moreover, it cannot be forgotten that tumor growth is able to modulate host metabolism and homeostasis, so that tumor microenvironment is not the whole story. Importantly, the metabolic switch in cancer is just a consequence of the flexibility and adaptability of metabolism and should not be surprising. Treatments of cancer patients with combined therapies including anti-tumor agents with those targeting stromal cell metabolism, anti-angiogenic drugs and/or immunotherapy are being developed as promising therapeutics.Mª Carmen Ocaña is recipient of a predoctoral FPU grant from the Spanish Ministry of Education, Culture and Sport. Supported by grants BIO2014-56092-R (MINECO and FEDER), P12-CTS-1507 (Andalusian Government and FEDER) and funds from group BIO-267 (Andalusian Government). The "CIBER de Enfermedades Raras" is an initiative from the ISCIII (Spain). The funders had no role in the study design, data collection and analysis, decision to publish or preparation of the manuscript

Interventions to optimise prescribing for older people in care homes

Background There is a substantial body of evidence that prescribing for care home residents is suboptimal and requires improvement. Consequently, there is a need to identify effective interventions to optimise prescribing and resident outcomes in this context. This is an update of a previously published review (Alldred 2013). Objectives The objective of the review was to determine the effect of interventions to optimise overall prescribing for older people living in care homes. Search methods For this update, we searched the Cochrane Central Register of Controlled Trials (CENTRAL) (including the Cochrane Effective Practice and Organisation of Care (EPOC) Specialised Register), MEDLINE, EMBASE and CINAHL to May 2015. We also searched clinical trial registries for relevant studies. Selection criteria We included randomised controlled trials evaluating interventions aimed at optimising prescribing for older people (aged 65 years or older) living in institutionalised care facilities. Studies were included if they measured one or more of the following primary outcomes: adverse drug events; hospital admissions; mortality; or secondary outcomes, quality of life (using validated instrument); medication-related problems; medication appropriateness (using validated instrument); medicine costs. Data collection and analysis Two authors independently screened titles and abstracts, assessed studies for eligibility, assessed risk of bias and extracted data. We presented a narrative summary of results. Main results The 12 included studies involved 10,953 residents in 355 (range 1 to 85) care homes in ten countries. Nine studies were cluster-randomised controlled trials and three studies were patient-randomised controlled trials. The interventions evaluated were diverse and often multifaceted. Medication review was a component of ten studies. Four studies involved multidisciplinary case-conferencing, five studies involved an educational element for health and care professionals and one study evaluated the use of clinical decision support technology. We did not combine the results in a meta-analysis due to heterogeneity across studies. Interventions to optimise prescribing may lead to fewer days in hospital (one study out of eight; low certainty evidence), a slower decline in health-related quality of life (one study out of two; low certainty evidence), the identification and resolution of medication-related problems (seven studies; low certainty evidence), and may lead to improved medication appropriateness (five studies out of five studies; low certainty evidence). We are uncertain whether the intervention improves/reduces medicine costs (five studies; very low certainty evidence) and it may make little or no difference on adverse drug events (two studies; low certainty evidence) or mortality (six studies; low certainty evidence). The risk of bias across studies was heterogeneous. Authors' conclusions We could not draw robust conclusions from the evidence due to variability in design, interventions, outcomes and results. The interventions implemented in the studies in this review led to the identification and resolution of medication-related problems and improvements in medication appropriateness, however evidence of a consistent effect on resident-related outcomes was not found. There is a need for high-quality cluster-randomised controlled trials testing clinical decision support systems and multidisciplinary interventions that measure well-defined, important resident-related outcomes